122 related articles for article (PubMed ID: 25096509)
21. A functional variant (-1304T>G) in the MKK4 promoter contributes to a decreased risk of lung cancer by increasing the promoter activity.
Liu B; Chen D; Yang L; Li Y; Ling X; Liu L; Ji W; Wei Y; Wang J; Wei Q; Wang L; Lu J
Carcinogenesis; 2010 Aug; 31(8):1405-11. PubMed ID: 20554746
[TBL] [Abstract][Full Text] [Related]
22. Identification of an inhibitory cis-element in the promoter region of human homeobox gene NKX3.1.
Anli J; Pengju Z; Xiaoyan H; Wenwei C; Zhifang L; Feng K; Huiqing Y; Jianye Z
Prostate; 2006 Sep; 66(12):1339-46. PubMed ID: 16845664
[TBL] [Abstract][Full Text] [Related]
23. A novel single nucleotide polymorphism in XRCC4 gene is associated with gastric cancer susceptibility in Taiwan.
Chiu CF; Wang CH; Wang CL; Lin CC; Hsu NY; Weng JR; Bau DT
Ann Surg Oncol; 2008 Feb; 15(2):514-8. PubMed ID: 17987338
[TBL] [Abstract][Full Text] [Related]
24. A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression.
Akamatsu S; Takata R; Ashikawa K; Hosono N; Kamatani N; Fujioka T; Ogawa O; Kubo M; Nakamura Y; Nakagawa H
Hum Mol Genet; 2010 Nov; 19(21):4265-72. PubMed ID: 20716579
[TBL] [Abstract][Full Text] [Related]
25. Gene variants of XRCC4 and XRCC3 and their association with risk for urothelial bladder cancer.
Mittal RD; Gangwar R; Mandal RK; Srivastava P; Ahirwar DK
Mol Biol Rep; 2012 Feb; 39(2):1667-75. PubMed ID: 21617942
[TBL] [Abstract][Full Text] [Related]
26. X-ray repair cross-complementing group 4 (XRCC4) promoter -1394( *)T-related genotype, but not XRCC4 codon 247/intron 3 or xeroderma pigmentosum group D codon 312, 751/promoter -114, polymorphisms are correlated with higher susceptibility to myoma.
Hsieh YY; Chang CC; Bau DT; Yeh LS; Tsai FJ; Tsai CH
Fertil Steril; 2008 Oct; 90(4 Suppl):1417-23. PubMed ID: 18177646
[TBL] [Abstract][Full Text] [Related]
27. A new single nucleotide polymorphism in XRCC4 gene is associated with breast cancer susceptibility in Taiwanese patients.
Chiu CF; Wang HC; Wang CH; Wang CL; Lin CC; Shen CY; Chiang SY; Bau DT
Anticancer Res; 2008; 28(1A):267-70. PubMed ID: 18383855
[TBL] [Abstract][Full Text] [Related]
28. The diagnostic value of DNA repair gene in breast cancer metastasis.
Yang Y; Li X; Hao L; Jiang D; Wu B; He T; Tang Y
Sci Rep; 2020 Nov; 10(1):19626. PubMed ID: 33184404
[TBL] [Abstract][Full Text] [Related]
29. [The study of esophageal cancer risk associated with polymorphisms of DNA damage repair genes XRCC4 and RAD51].
Fan XJ; Ren PL; Lu ZJ; Zhao S; Yang XL; Liu J
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Jul; 44(4):568-72. PubMed ID: 24059110
[TBL] [Abstract][Full Text] [Related]
30. Do polymorphisms in XRCC4 influence prostate cancer susceptibility in North Indian population?
Mandal RK; Singh V; Kapoor R; Mittal RD
Biomarkers; 2011 May; 16(3):236-42. PubMed ID: 21506695
[TBL] [Abstract][Full Text] [Related]
31. Sp1-mediated transcriptional control of fibroblast growth factor receptor 4 in sarcomas of skeletal muscle lineage.
Yu SJ; Zheng L; Ladanyi M; Asa SL; Ezzat S
Clin Cancer Res; 2004 Oct; 10(19):6750-8. PubMed ID: 15475466
[TBL] [Abstract][Full Text] [Related]
32. Susceptibility to gastric cancer and polymorphisms of insertion/deletion at the intron 3 of the XRCC4 and VNTR at the promoter region of the XRCC5.
Saadat M; Pashaei S; Amerizade F
Pathol Oncol Res; 2015 Jul; 21(3):689-93. PubMed ID: 25527410
[TBL] [Abstract][Full Text] [Related]
33. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels.
Cramer SD; Chang BL; Rao A; Hawkins GA; Zheng SL; Wade WN; Cooke RT; Thomas LN; Bleecker ER; Catalona WJ; Sterling DA; Meyers DA; Ohar J; Xu J
J Natl Cancer Inst; 2003 Jul; 95(14):1044-53. PubMed ID: 12865450
[TBL] [Abstract][Full Text] [Related]
34. Electrophoretic mobility shift assays implicate XRCC2:rs3218550C>T as a potential low-penetrant susceptibility allele for sporadic breast cancer.
Sirisena ND; Samaranayake N; Dissanayake VHW
BMC Res Notes; 2019 Aug; 12(1):476. PubMed ID: 31370865
[TBL] [Abstract][Full Text] [Related]
35. Functional promoter SNPs in cell cycle checkpoint genes.
Bélanger H; Beaulieu P; Moreau C; Labuda D; Hudson TJ; Sinnett D
Hum Mol Genet; 2005 Sep; 14(18):2641-8. PubMed ID: 16081466
[TBL] [Abstract][Full Text] [Related]
36. TWIST2: A new candidate tumor suppressor in prostate cancer.
Zhao C; Zhang W; Zhu X; Xu Y; Yang K; Wei D; Liang S; Zhao F; Zhang Y; Chen X; Sun L; Yuan H; Shi X; Wang X; Liu M; Yang F; Wang J; Yang Z
Prostate; 2019 Oct; 79(14):1647-1657. PubMed ID: 31433071
[TBL] [Abstract][Full Text] [Related]
37. A novel DNA-binding motif in prostate tumor overexpressed-1 (PTOV1) required for the expression of ALDH1A1 and CCNG2 in cancer cells.
Maggio V; Cánovas V; Félix AJ; Gómez V; de Torres I; Semidey ME; Morote J; Noé V; Ciudad CJ; Paciucci R
Cancer Lett; 2019 Jun; 452():158-167. PubMed ID: 30922918
[TBL] [Abstract][Full Text] [Related]
38. Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression.
Cheng L; Qiu L; Wang M; Zhang R; Sun M; Zhu X; Wang Y; Wei Q
Mol Carcinog; 2017 Dec; 56(12):2706-2717. PubMed ID: 28796378
[TBL] [Abstract][Full Text] [Related]
39. Functional Study of Polymorphism 1888 C>T in the Promoter Region of Human PLUNC Gene.
Liu B; Wang R; He Y
Am J Med Sci; 2021 Mar; 361(3):358-364. PubMed ID: 33722345
[TBL] [Abstract][Full Text] [Related]
40. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.
Shin S; Kim TD; Jin F; van Deursen JM; Dehm SM; Tindall DJ; Grande JP; Munz JM; Vasmatzis G; Janknecht R
Cancer Res; 2009 Oct; 69(20):8102-10. PubMed ID: 19789348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
